Literature DB >> 18514247

Characterizing interspecies uncertainty using data from studies of anti-neoplastic agents in animals and humans.

Paul S Price1, Russell E Keenan, Jeffrey C Swartout.   

Abstract

For most chemicals, the Reference Dose (RfD) is based on data from animal testing. The uncertainty introduced by the use of animal models has been termed interspecies uncertainty. The magnitude of the differences between the toxicity of a chemical in humans and test animals and its uncertainty can be investigated by evaluating the inter-chemical variation in the ratios of the doses associated with similar toxicological endpoints in test animals and humans. This study performs such an evaluation on a data set of 64 anti-neoplastic drugs. The data set provides matched responses in humans and four species of test animals: mice, rats, monkeys, and dogs. While the data have a number of limitations, the data show that when the drugs are evaluated on a body weight basis: 1) toxicity generally increases with a species' body weight; however, humans are not always more sensitive than test animals; 2) the animal to human dose ratios were less than 10 for most, but not all, drugs; 3) the current practice of using data from multiple species when setting RfDs lowers the probability of having a large value for the ratio. These findings provide insight into inter-chemical variation in animal to human extrapolations and suggest the need for additional collection and analysis of matched toxicity data in humans and test animals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18514247     DOI: 10.1016/j.taap.2008.03.026

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  8 in total

Review 1.  High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.

Authors:  Juan C Del Álamo; Derek Lemons; Ricardo Serrano; Alex Savchenko; Fabio Cerignoli; Rolf Bodmer; Mark Mercola
Journal:  Biochim Biophys Acta       Date:  2016-03-04

Review 2.  A Unified Probabilistic Framework for Dose-Response Assessment of Human Health Effects.

Authors:  Weihsueh A Chiu; Wout Slob
Journal:  Environ Health Perspect       Date:  2015-05-22       Impact factor: 9.031

Review 3.  Can Human Pluripotent Stem Cell-Derived Cardiomyocytes Advance Understanding of Muscular Dystrophies?

Authors:  Spandan Kalra; Federica Montanaro; Chris Denning
Journal:  J Neuromuscul Dis       Date:  2016-08-30

4.  Distributions for time, interspecies and intraspecies extrapolation for deriving occupational exposure limits.

Authors:  Marco Dilger; Klaus Schneider; Claudia Drossard; Heidi Ott; Eva Kaiser
Journal:  J Appl Toxicol       Date:  2022-03-13       Impact factor: 3.628

Review 5.  Dispelling urban myths about default uncertainty factors in chemical risk assessment--sufficient protection against mixture effects?

Authors:  Olwenn V Martin; Scholze Martin; Andreas Kortenkamp
Journal:  Environ Health       Date:  2013-07-01       Impact factor: 5.984

Review 6.  Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Afford New Opportunities in Inherited Cardiovascular Disease Modeling.

Authors:  Daniel R Bayzigitov; Sergey P Medvedev; Elena V Dementyeva; Sevda A Bayramova; Evgeny A Pokushalov; Alexander M Karaskov; Suren M Zakian
Journal:  Cardiol Res Pract       Date:  2016-03-27       Impact factor: 1.866

7.  Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.

Authors:  Chris Denning; Viola Borgdorff; James Crutchley; Karl S A Firth; Vinoj George; Spandan Kalra; Alexander Kondrashov; Minh Duc Hoang; Diogo Mosqueira; Asha Patel; Ljupcho Prodanov; Divya Rajamohan; William C Skarnes; James G W Smith; Lorraine E Young
Journal:  Biochim Biophys Acta       Date:  2015-10-31

Review 8.  Current status of drug screening and disease modelling in human pluripotent stem cells.

Authors:  Divya Rajamohan; Elena Matsa; Spandan Kalra; James Crutchley; Asha Patel; Vinoj George; Chris Denning
Journal:  Bioessays       Date:  2012-08-08       Impact factor: 4.345

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.